Drug Monograph

Drug Name: **Hetlioz LQ™ (tasimelteon) Suspension**
Drug Class: **CNS: Sedative Hypnotics, Non-Benzodiazepines, Melatonin Receptor Agonists**
Prepared For: MO HealthNet
Prepared By: Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Hetlioz LQ is available as a 4 mg/ml oral suspension.
Manufacturer:	Distributed by: Vanda Pharmaceuticals, Inc., Washington, D.C. 20037.
Indications:	Hetlioz LQ is a melatonin receptor agonist indicated for the treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in pediatric patients 3 years to 15 years of age.
Costs:	$20,131.89 per 150 ml of 4 mg/ml of Hetlioz LQ Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred.
Status Recommendation:	☐ Clinical Edit ☐ PA Required ☐ Open Access ☒ PDL
Type of PA Criteria:	☐ Appropriate Indications ☒ Non-Preferred ☐ No PA Required ☐ Preferred

Prepared by: April Ash, PharmD
Date: May 13, 2021

© 2021 Conduent Business Services, LLC All Rights Reserved.